A Clinical Comparative Study Between Ticagrelor and Clopidogrel for Treating the Patients With Acute ST-segment Elevation Myocardial Infarction
10.3969/j.issn.1000-3614.2014.08.005
- VernacularTitle:替格瑞洛与氯吡格雷对急性ST段抬高型心肌梗死的临床疗效对比研究
- Author:
Haibo WANG
;
Yijie HUANG
;
Qiang WU
;
Wen LU
;
Yi LIU
- Publication Type:Journal Article
- Keywords:
Acute coronary syndrome;
Ticagrelor;
Clopidogrel;
Anti-platelet coagulation;
Acute ST-segment elevation myocardial infarction
- From:
Chinese Circulation Journal
2014;(8):574-577
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To explore the clinical efficacy of a new drug for acute coronary syndrome (ACS), ticagrelor in treating the patients with acute ST-segment elevation myocardial infarction (STEMI), and to compare the effect between ticagrelor and clopidogrel in order to obtain the prospective information of ticagrelor in clinical practice.
Methods: A total of 307 STEMI patients were divided into 2 groups, Treatment group, the patients received ticagrelor with aspirin, n=157 and Control group, the patients received clopidogrel with aspirin, n=150. With a period of treatment, the major adverse cardiac events (MACE), rate of thrombosis re-formation and routine blood test result were compared between 2 groups.
Results: Treatment group presented the better LVDD, LVEF, platelet level and ST-segment recovery than those in Control group, P<0.05 or P<0.01. Treatment group showed slightly higher rate of side effect such as dififcult breathing and bleeding, while those reaction did not affect the treatment or special management for the patients.
Conclusion: The clinical effect of ticagrelor is similar to clopidogre for improving the platelet level and cardiac function in STEMI patients, while the clinical advantage reported in abroad should be further studied.